Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

News

  • 09/01/2025
  • Press Release

STADA sets course for the future - experienced healthcare manager Andreas Fibig to become Chairman of the Board

  • STADA has retained Andreas Fibig as independent Chairman of its future Board of Directors

  • The Board of Directors will be established in the event of an IPO of STADA and will have a total of nine members

  • STADA CEO Peter Goldschmidt: “Andreas Fibig is an excellent choice as our candidate for the position of Chairman of the Board of Directors of STADA. His global experience and outstanding expertise, especially in the healthcare sector, would help us enormously.”

Bad Vilbel, Germany – 09 January 2025 – At the turn of the year, STADA's owners Cinven and Bain Capital are setting the course for the future. No decision has yet been taken; various options are under consideration, including an initial public offering (IPO). In the event of an IPO, the Board of Directors will become the top leadership body of the German healthcare company and Andreas Fibig will assume the role of the independent Chairman of STADA’s Board of Directors. With Andreas Fibig, STADA has secured an internationally experienced top manager with outstanding expertise in the pharmaceutical and consumer healthcare sectors.

The 62-year-old former Chief Executive Officer (CEO) of International Flavors & Fragrances Inc. would become the independent Chairman of STADA's Board of Directors.

“Andreas Fibig is an excellent choice as our candidate for the position of Chairman of the Board of Directors of STADA. His global experience and outstanding expertise, especially in the healthcare sector, would help us enormously. Andreas shares our ‘Culture drives Performance‘ mindset. I look forward to working with him,“ commented STADA CEO Peter Goldschmidt.

“I am very honored to assume the role of Chairman of the Board of Directors at STADA in the event of an IPO. With its broad and strong product portfolio, STADA is one of the fastest-growing Consumer Healthcare companies worldwide and a major player as well in Generics and Specialty Pharmaceuticals. I am particularly impressed by the growth-oriented corporate culture under the leadership of Peter Goldschmidt and his team,” said Andreas Fibig.

Fibig spent 10 years with International Flavors & Fragrances (NYSE: IFF), an industry leader in food ingredients, beverage, scent, health care and biosciences, including seven years as Chairman and CEO. There, he established a record of driving strong growth as well as leading the company through significant transformation, including the integration of DuPont Nutrition & Biosciences following a merger. Prior to that, he served as president and chairman of the board of management for Bayer Health Care Pharmaceuticals, where he was the chief executive responsible for Bayer's global health care and pharmaceutical business. He currently serves on the board of Novo-Nordisk A/S (NYSE: NVO), where he is an independent director and member of the Research and Development Committee.  He also serves as a director in the Board of ExlService Holdings, a leading global data analytics and digital operations and solutions company.

The Board of Directors will be established at STADA's future listed Group holding company, which will be incorporated under Dutch law, but based in Germany. It will compromise of the Chief Executive Officer and the Chief Financial Officer of STADA as Executive Directors and seven further Directors, including the Chairman, with supervisory functions (Non-Executive Directors). 

Andreas Fibig

Download


Disclaimer
Neither this communication nor the publication in which it is contained is for publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America, including its territories and possessions, any state of the United States and the District of Columbia (the “United States”). This communication is not and does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, Australia, Canada or Japan, or any other jurisdiction in which such offer may be restricted or unlawful.

Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, subscribed, used, pledged, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements under the Securities Act, and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States.


About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in more than 100 countries. In financial year 2023, STADA achieved group revenues of EUR 3,734.8 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 802.1 million. As of 31 December 2023, STADA employed 11,667 people worldwide.

Additional information for journalists
STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18
61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
E-Mail: [email protected]
Follow @STADAGroup on LinkedIn

Additional information for capital market participants
STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18
61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: [email protected]